[1]
|
Kamisawa, T., Funata, N., Hayashi, Y., et al. (2003) A New Clinicopathological Entity of IgG4-Related Autoimmune Disease. Journal of Gastroenterology, 38, 982-984. https://doi.org/10.1007/s00535-003-1175-y
|
[2]
|
Inoue, D., Yoshida, K., Yoneda, N., et al. (2015) IgG4-Related Disease: Dataset of 235 Consecutive Patients. Medicine (Baltimore), 94, e680. https://doi.org/10.1097/MD.0000000000000680
|
[3]
|
Deshpande, V., Zen, Y., Chan, J.K., et al. (2012) Consensus Statement on the Pathology of IgG4-Related Disease. Modern Pathology, 25, 1181-1192. https://doi.org/10.1038/modpathol.2012.72
|
[4]
|
Zen, Y., Inoue, D., Kitao, A., et al. (2009) IgG4-Related Lung and Pleural Disease: A Clinicopathologic Study of 21 Cases. American Journal of Surgical Pathology, 33, 1886-1893. https://doi.org/10.1097/PAS.0b013e3181bd535b
|
[5]
|
Morales, A.T., Cignarella, A.G., Jabeen, I.S., et al. (2019) An Update on IgG4-Related Lung Disease. European Journal of Internal Medicine, 66, 18-24. https://doi.org/10.1016/j.ejim.2019.06.010
|
[6]
|
Carruthers, M.N., Khosroshahi, A., Augustin, T., et al. (2015) The Diagnostic Utility of Serum IgG4 Concentrations in IgG4-Related Disease. Annals of Rheumatic Diseases, 74, 14-18. https://doi.org/10.1136/annrheumdis-2013-204907
|
[7]
|
Wallace, Z.S., Naden, R.P., Chari, S., et al. (2020) The 2019 American College of Rheumatology/European League against Rheumatism Classification Criteria for IgG4-Related Disease. Arthritis & Rheumatology, 72, 7-19.
https://doi.org/10.1002/art.41120
|
[8]
|
Corcoran, J.P., Culver, E.L., Anstey, R.M., et al. (2017) Thoracic Involve-ment in IgG4-Related Disease in a UK-Based Patient Cohort. Respiratory Medicine, 132, 117-121. https://doi.org/10.1016/j.rmed.2017.10.005
|
[9]
|
Saraya, T., Ohkuma, K., Fujiwara, M., Miyaoka, C., et al. (2017) Clinical Characterization of 52 Patients with Immunoglobulin G4-Related Disease in a Single Tertiary Center in Japan: Special Reference to Lung Disease in Thoracic High-Resolution Computed Tomography. Respiratory Medicine, 132, 62-67.
https://doi.org/10.1016/j.rmed.2017.09.006
|
[10]
|
Kamisawa, T., Zen, Y., Pillai, S., et al. (2015) IgG4-Related Dis-ease. The Lancet, 385, 1460-1471.
https://doi.org/10.1016/S0140-6736(14)60720-0
|
[11]
|
Clerc, A., Reynaud, Q., Durupt, S., et al. (2017) Elevated IgG4 Serum Levels in Patients with Cystic Fibrosis. PLOS ONE, 12, e0181888. https://doi.org/10.1371/journal.pone.0181888
|
[12]
|
Ebbo, M., Grados, A., Bernit, E., et al. (2012) Pathologies As-sociated with Serum IgG4 Elevation. International Journal of Rheumatology, 2012, Article ID: 602809. https://doi.org/10.1155/2012/602809
|
[13]
|
Koneczny, I. (2020) Update on IgG4-Mediated Autoimmune Diseases: New Insights and New Family Members. Autoimmunity Reviews, 19, Article ID: 102646. https://doi.org/10.1016/j.autrev.2020.102646
|
[14]
|
Yu, T., Wu, Y., Liu, J., et al. (2022) The Risk of Malignancy in Patients with IgG4-Related Disease: A Systematic Review and Meta-Analysis. Arthritis Research & Therapy, 24, 14. https://doi.org/10.1186/s13075-021-02652-2
|
[15]
|
Yamamoto, M., Yajima, H., Takahashi, H., et al. (2015) Every-day Clinical Practice in IgG4-Related Dacryoadenitis and/or Sialadenitis: Results from the SMART Database. Modern Rheumatology, 25, 199-204.
https://doi.org/10.3109/14397595.2014.950036
|
[16]
|
Khan, M.L., Colby, T.V., Viggiano, R.W., et al. (2010) Treatment with Bortezomib of a Patient Having Hyper IgG4 Disease. Clinical Lymphoma Myeloma & Leukemia, 10, 217-219. https://doi.org/10.3816/CLML.2010.n.034
|
[17]
|
Skorda, A., Sklirou, A.D., Sakellaropoulos, T., Gianniou, D.D., Kastritis, E., et al. (2019) Non-Lethal Proteasome Inhibition Activates Pro-Tumorigenic Pathways in Multiple My-eloma Cells. Journal of Cellular and Molecular Medicine, 23, 8010-8018. https://doi.org/10.1111/jcmm.14653
|
[18]
|
Neubert, K., Meister, S., Moser, K., et al. (2008) The Proteasome Inhibi-tor Bortezomib Depletes Plasma Cells and Protects Mice with Lupus-Like Disease from Nephritis. Nature Medicine, 14, 748-755. https://doi.org/10.1038/nm1763
|
[19]
|
Chang, C.C., Aversa, G., Punnonen, J., et al. (1993) Brequinar So-dium, Mycophenolic Acid, and Cyclosporin A Inhibit Different Stages of IL-4- or IL-13-Induced Human IgG4 and IgE Production in Vitro. Annals of the New York Academy of Sciences, 696, 108-122. https://doi.org/10.1111/j.1749-6632.1993.tb17146.x
|
[20]
|
Sun, X., Liu, H., Feng, R., et al. (2016) Biopsy-Proven IgG4-Related Lung Disease. BMC Pulmonary Medicine, 16, Article No. 20. https://doi.org/10.1186/s12890-016-0181-9
|
[21]
|
Betancur-Vsquez, L., Gonzalez-Hurtado, D., Arango-Isaza, D., et al. (2020) IgG4-Related Disease: Is Rituximab the Best Therapeutic Strategy for Cases Refractory to Conventional Ther-apy? Results of a Systematic Review. Reumatología Clínica (English Edition), 16, 195-202. https://doi.org/10.1016/j.reumae.2018.11.019
|
[22]
|
Otani, K., Inoue, D., Itoh, T., et al. (2018) Transbronchial Lung Biopsy for the Diagnosis of IgG4-Related Lung Disease. Histopathology, 73, 49-58. https://doi.org/10.1111/his.13513
|